Drug intelligence / Profile preview

insulin B chain vaccine

Development stage: Phase 1
Lead developer: Orban Biotech
Modality: Vaccines & Immunotherapeutics

Overview

Insulin B chain vaccine (IBC-VS01) is a therapeutic vaccine developed by Orban Biotech for the treatment and prevention of Type 1 Diabetes Mellitus (T1DM). The drug originated from research conducted at the Joslin Diabetes Center and aims to modulate the immune response related to the insulin B chain, which is implicated in the autoimmune destruction of insulin-producing beta cells in T1DM.

Targets

Insulin B chain epitope-specific T-cell receptor

Beyond the preview

Go deeper on insulin B chain vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin B chain vaccine.

Explore the full profile